Human Anti-PCSK9 Recombinant Antibody (clone mAb1) (CAT#: PABL-294)

Recombinant Human Antibody (mAb1) is capable of binding to PCSK9, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-PCSK9 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-PCSK9 mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody could block interaction of PCSK9 with the epidermal growth factor-like repeat A domain of LDL receptor (LDLR)


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 In vitro effect of mAb1.

Figure 1 In vitro effect of mAb1.

(A) mAb1 induced LDLR protein in HepG2 cells after 24 and 48 h, as assessed by Western blot analysis. (B) mAb1 increased LDLR protein in a HepG2 stable cell line overexpressing PCSK9. Cells were incubated with mAb1 for 24 h. The fold change in a and b was calculated as the ratio of LDLR in the presence of mAb1 to LDLR in the absence of mAb1, after normalization of LDLR to β-actin in each lane. (C) A combination of mAb1 with mevinolin induces LDLR protein more than either treatment alone. HepG2 cells were incubated with mAb1 (1, 3, or 10 μg/mL) with or without mevinolin (0.2 or 1 μg/mL) for 48 h, followed by Western blot analysis of whole-cell lysates. The fold change in c was calculated as the ratio of LDLR in the presence of mAb1 and/or mevinolin to LDLR in the untreated cells, after normalization of LDLR to β-actin in each lane.

Figure 2 Changes in serum total cholesterol after i.v. administration of mAb1 to C57BL/6 mice.

Figure 2 Changes in serum total cholesterol after i.v. administration of mAb1 to C57BL/6 mice.

(A) Injection of 10 mg/kg mAb1 caused a statistically significant decrease in TC. Results are expressed as the mean ± SEM, n = 7 per group. (B) mAb1 induced hepatic LDLR protein expression, as assessed by Western blot analysis of pooled liver lysates. The fold change was calculated as the ratio of LDLR in the presence or absence of mAb1 for each time point after normalization of the LDLR to β-actin in each lane. (C) mAb1 dose-dependently lowered serum non-HDL-C in mice expressing huPCSK9 by adeno-associated virus (AAV) (n = 7 per treatment group). Results are expressed as the mean ± SEM. *P < 0.05; **P < 0.01 vs. anti-KLH control antibody at the same time point and dose.

Figure 3 Changes in serum LDL-C after i.v. administration of mAb1 to cynomolgus monkeys.

Figure 3 Changes in serum LDL-C after i.v. administration of mAb1 to cynomolgus monkeys.

A single injection of mAb1 led to (A) a significant lowering of serum TC, observed as early as 8 h after administration of mAb1; (B) a significant lowering in serum LDL-C, with maximal lowering observed at 10 days after injection; and (C) a significant lowering of HDL-C at day 3 and day 7. Results are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 vs. anti-KLH control antibody at the same time point, n = 4 per group. (D) Temporal relationship between free circulating PCSK9 levels and serum LDL-C after administration of mAb1.


Specifications

  • Immunogen
  • Human proprotein convertase subtilisin/kexin type 9
  • Host Species
  • Human
  • Type
  • Human IgG
  • Specificity
  • Human PCSK9
  • Species Reactivity
  • Human
  • Clone
  • mAb1
  • Applications
  • WB, Block, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • PCSK9; proprotein convertase subtilisin/kexin type 9; FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; convertase subtilisin/kexin type 9 preproprotein

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone mAb1"

See other products for "PCSK9"

Humanized Antibody

Single-domain Antibody

CAT Product Name Application Type
TAB-0080CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKE2) FuncS, Inhib, FC, WB Single domain antibody
TAB-0081CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKF8) FuncS, Inhib, FC, WB Single domain antibody
TAB-0082CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKG1) FuncS, Inhib, FC, WB Single domain antibody
TAB-0083CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (P1.70) FuncS, Inhib, FC, WB Single domain antibody
TAB-0084CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKE1) FuncS, Inhib, FC, WB Single domain antibody

Neutralizing Antibody

CAT Product Name Application Type
NEUT-1826CQ Recombinant Human Anti-PCSK9 Antibody, Unconjugated Neut IgG1

Rabbit Monoclonal Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-758 Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Lodelcizumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-H10 Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Bococizumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS ADCC enhanced antibody
AFC-TAB-H59 Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Ralpancizumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-H31 Afuco™ Anti-PCSK9 Recombinant Antibody (AFC-TAB-H31), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF Human IgG1, λ

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-294. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare